Browsing Tag

TLX591-CDx

Japanese Prostate Cancer Imaging Trial Meets Study Objectives

Eli Pacheco Feb 8, 2022 0

MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today…

Health

FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®

Eli Pacheco Dec 20, 2021 0

MELBOURNE, Australia and INDIANAPOLIS, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a global biopharmaceutical company focused on the…

Health

Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil

Eli Pacheco Dec 1, 2021 0

MELBOURNE, Australia and PORTO ALEGRE, Brazil, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Brazilian Health…

Health

Two New Studies to Explore Telix Assets in Breast Cancer Theranostics

Eli Pacheco Aug 18, 2021 0

Breast cancer one of several important indication expansion opportunities for the Telix portfolioFirst patient dosed at Emory University (Atlanta, USA) in a Phase I study of TLX591-CDx for…